Microscopic Colitis: What Do We Know about Pathogenesis?

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 450-458

  Pisani, Laura Francesca ^a   Tontini, Gian Eugenio ^a   Vecchi, Maurizio ^a,b   Pastorelli, Luca ^a,b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

collagenous colitis; inflammation; lymphocytic colitis; microscopic colitis; pathogenesis

Indexed keywords

MICRORNA;

ADAPTIVE IMMUNITY; CLINICAL FEATURE; COLLAGENOUS COLITIS; COLON CARCINOGENESIS; DRUG INDUCED DISEASE; DRUG INDUCED MICROSCOPIC COLITIS; GENETICS; HUMAN; INNATE IMMUNITY; LYMPHOCYTIC COLITIS; MICROSCOPIC COLITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; COLITIS, MICROSCOPIC; INCIDENCE; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE;

COLITIS, MICROSCOPIC; HUMANS; INCIDENCE; PROGNOSIS; QUALITY OF LIFE;

EID: 84955573117     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000628     Document Type: Review

References (100)

1. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology. 2011;140: 1155-1165.
2. Ingle SB, Adgaonkar BD, Ingle CR. Microscopic colitis: common cause of unexplained nonbloody diarrhea. World J Gastrointest Pathophysiol. 2014;5:48-53.
3. Münch A, Aust D, Bohr J, et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis. 2012;6:932-945.
4. Langner C, Aust D, Ensari A, et al. Histology of microscopic colitis-review with a practical approach for pathologists. Histopathology. 2015; 66:613-626.
5. Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004;53:536-541.
6. Yung DE, Koulaouzidis A, Fineron P, et al. Microscopic colitis: a misnomer for a clearly defined entity? Endoscopy. 2015;47:754-757.
7. Koulaouzidis A, Saeed AA. Distinct colonoscopy findings of microscopic colitis: not so microscopic after all? World J Gastroenterol. 2011;17:4157-4165.
8. Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minn. Gut. 2007;56:504-508.
9. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996; 39:846-851.
10. Tontini GE, Pastorelli L, Spina L, et al. Microscopic colitis and colorec-tal neoplastic lesion rate in chronic nonbloody diarrhea: a prospective, multicenter study. Inflamm Bowel Dis. 2014;20:882-891.
11. Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut. 2004;53:346-350.
12. Tysk C, Wickbom A, Nyhlin N, et al. Recent advances in diagnosis and treatment of microscopic colitis. Ann Gastroenterol. 2011;24:253-262.
13. Rasmussen MA, Munck LK. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease-microscopic colitis? Aliment Pharmacol Ther. 2012;36:79-90.
14. Koskela RM, Karttunen TJ, Niemela SE, et al. Cytokine gene polymorphism in microscopic colitis association with the IL-6-174 GG genotype. Eur J Gastroenterol Hepatol. 2011;23:607-613.
15. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(suppl 2):S3.
16. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531-536.
17. Korn T, Mitsdoerffer M, Croxford AL, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2008;105:18460-18465.
18. Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 2014;40:40-50.
19. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. 2011;2011:721608.
20. Fine KD, Do K, Schulte K, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol. 2000;95:1974-1982.
21. Fernandez-Banares F, Esteve M, Farre C, et al. Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis. Eur J Gastroenterol Hepatol. 2005;17:1333-1338.
22. Hellmig S, Ott S, Rosenstiel P, et al. Genetic variants in matrix metal-loproteinase genes are associated with development of gastric ulcer in H. pylori infection. Am J Gastroenterol. 2006;101:29-35.
23. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
24. O'Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015;2015: 964131.
25. Madisch A, Hellmig S, Schreiber S, et al. Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis. Inflamm Bowel Dis. 2011;17:2295-2298.
26. Shogan BD, Belogortseva N, Luong PM, et al. Collagen degradation and MMP9 activation by enterococcus faecalis contribute to intestinal anas-tomotic leak. Sci Transl Med. 2015;7:286ra268.
27. Sikander A, Sinha SK, Prasad KK, et al. Association of serotonin transporter promoter polymorphism (5-HTTLPR) with microscopic colitis and ulcerative colitis. Dig Dis Sci. 2015;60:887-894.
28. Jarnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109:449-455.
29. Tagkalidis PP, Gibson PR, Bhathal PS. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol. 2007;60: 382-387.
30. Gunaltay S, Nyhlin N, Kumawat AK, et al. Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis. World J Gastroenterol. 2014;20:12249-12259.
31. Johrens K, Grunbaum M, Anagnostopoulos I. Differences in the T-bet and GATA-3 expression patterns between lymphocytic colitis and coe-liac disease. Virchows Arch. 2010;457:451-456.
32. Goranzon C, Kumawat AK, Hultgren-Hornqvist E, et al. Immunohisto-chemical characterization of lymphocytes in microscopic colitis. J Crohns Colitis. 2013;7:e434-e442.
33. Kumawat AK, Strid H, Elgbratt K, et al. Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells. J Crohns Colitis. 2013;7:694-705.
34. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271-2279.
35. Maloy KJ. The Interleukin-23/Interleukin-17 axis in intestinal inflammation. J Intern Med. 2008;263:584-590.
36. Han L, Yang J, Wang X, et al. Th17 cells in autoimmune diseases. Front Med. 2015;9:10-19.
37. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763-776.
38. Kumawat AK, Strid H, Tysk C, et al. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol. 2013;55:355-364.
39. Shibahara T, Wilcox JN, Couse T, et al. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gas-troenterology. 2001;120:60-70.
40. Sugi K, Musch MW, Field M, et al. Inhibition of Na+, K+-ATPase by interferon gamma down-regulates intestinal epithelial transport and barrier function. Gastroenterology. 2001;120:1393-1403.
41. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of inter-leukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-1636.
42. Lexberg MH, Taubner A, Albrecht I, et al. IFN-gamma and IL-12 syn-ergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol. 2010;40:3017-3027.
43. Yen HR, Harris TJ, Wada S, et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol. 2009;183:7161-7168.
44. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008; 9:650-657.
45. Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol. 2009;182:5296-5305.
46. Seiderer J, Elben I, Diegelmann J, et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.Hi-s161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008;14:437-445.
47. Daferera N, Kumawat AK, Hultgren-Hörnquist E, et al. Fecal stream diversion and mucosal cytokine levels in collagenous colitis: a case report. World J Gastroenterol. 2015;21:6065-6071.
48. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci. 2009;30:441-447.
49. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology. 2008;134: 1038-1048.
50. Sarra M, Pallone F, Monteleone G. Interleukin-21 in chronic inflammatory diseases. Biofactors. 2013;39:368-373.
51. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12:383-390.
52. Kim K, Kim G, Kim JY, et al. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carci-nogenesis. 2014;35:1352-1361.
53. Salas A, Fernandez-Banares F, Casalots J, et al. Subepithelial myofibro-blasts and tenascin expression in microscopic colitis. Histopathology. 2003;43:48-54.
54. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014-1022.
55. Bai S, Siegal GP, Jhala NC. Foxp3 expression patterns in microscopic colitides: a clinicopathologic study of 69 patients. Am J Clin Pathol. 2012;137:931-936.
56. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28:109-123.
57. Rubio CA. Lysozyme expression in microscopic colitis. J Clin Pathol. 2011;64:510-515.
58. Olesen M, Middelveld R, Bohr J, et al. Luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in col-lagenous and lymphocytic colitis. Scand J Gastroenterol. 2003;38:66-72.
59. Lundberg JO, Herulf M, Olesen M, et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest. 1997;27:869-871.
60. Menconi MJ, Unno N, Smith M, et al. Nitric oxide donor-induced hyper-permeability of cultured intestinal epithelial monolayers: role of super-oxide radical, hydroxyl radical, and peroxynitrite. Biochim Biophys Acta. 1998;1425:189-203.
61. Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013;4:280.
62. Barmeyer C, Erko I, Fromm A, et al. Ion transport and barrier function are disturbed in microscopic colitis. Ann N Y Acad Sci. 2012;1258:143-148.
63. Bürgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123:433-443.
64. Lin J, Welker NC, Zhao Z, et al. Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol. 2014;27:602-608.
65. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807-821.
66. Zhang C, Zhao Z, Osman H, et al. Differential expression of miR-31 between inflammatory bowel disease and microscopic colitis. Microrna. 2014;3:155-159.
67. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129:1401-1414.
68. Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27: 91-105.
69. Olaru AV, Selaru FM, Mori Y, et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neo-plastic transformation. Inflamm Bowel Dis. 2011;17:221-231.
70. Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle. 2010;9:2124-2129.
71. Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481-12486.
72. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol. 2013;13:666-678.
73. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191-202.
74. O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295-312.
75. Wang P, Hou J, Lin L, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol. 2010;185: 6226-6233.
76. O'Connell RM, Chaudhuri AA, Rao DS, et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 2009;106:7113-7118.
77. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010;11:141-147.
78. Fernández-Bañares F, Esteve M, Espinós JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102: 324-330.
79. Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847.
80. Etienney I, Beaugerie L, Viboud C, et al. Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut. 2003;52:260-263.
81. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis. 1996; 55:211-213.
82. Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol. 2009;43:551-553.
83. Mullin JM, Gabello M, Murray LJ, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14:647-660.
84. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69:338-341.
85. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3-10.
86. Vesper BJ, Jawdi A, Altman KW, et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84-89.
87. Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropha-ryngeal microflora. J Pediatr. 2015;166:917-923.
88. Berrebi D, Sautet A, Flejou JF, et al. Ticlopidine induced colitis: a histopathological study including apoptosis. J Clin Pathol. 1998; 51:280-283.
89. Piche T, Raimondi V, Schneider S, et al. Acarbose and lymphocytic colitis. Lancet. 2000;356:1246.
90. Beaugerie L, Luboinski J, Brousse N, et al. Drug induced lymphocytic colitis. Gut. 1994;35:426-428.
91. Mukhopadhya A, Gilmour H, Plevris J. Pravastatin-induced colitis. Eur J Gastroenterol Hepatol. 2008;20:810-812.
92. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-296.
93. Rizzo A, Pallone F, Monteleone G, et al. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol. 2011; 17:3092-3100.
94. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
95. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol. 2005;124:10-14.
96. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
97. Heijmans J, Büller NV, Muncan V, et al. Rage mediated DAMP signaling in intestinal tumorigenesis. Oncoimmunology. 2012;1:1165-1166.
98. Nowacki TM, Brückner M, Eveslage M, et al. The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Sci. 2015;60:492-501.
99. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724-2729.
100. Andresen L, Jørgensen VL, Perner A, et al. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut. 2005;54:503-509.